- $19.39m
- $18.53m
- $0.07m
Brief: Lucid Diagnostics And Pavmed's Unit Embarked On Expansion Of Direct Contracting Initiative
Brief: Lucid Diagnostics Receives Notice Of Allowance For Key Patent Underlying Its Esoguard Esophageal DNA Test
Brief: PAVmed Determined That Lucid Diagnostics Inc And Its Subsidiaries Will Be Deconsolidated From Co's Financial Statements As Of Sept 10
Brief: Pavmed Announces Efforts To Regain Compliance With Nasdaq Listing Requirements
Brief: Lucid Diagnostics Signs Memorandum Of Understanding With Front Line Mobile Health
Brief: Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard
PAVmed Inc reports results for the quarter ended in June - Earnings Summary
PAVmed Inc expected to post a loss of $1.45 a share - Earnings Preview
Brief: Lucid Diagnostics Announces Positive Data From Its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study
Brief: Pavmed Subsidiary, Veris Health, Announces Launch Of Pilot Program With The Ohio State University Comprehensive Cancer Center - James Cancer Hospital And Solove Research Institute
U.S. RESEARCH ROUNDUP-Chord Energy, PVH, Saia
PAVmed Inc reports results for the quarter ended in March - Earnings Summary
PAVmed Inc expected to post a loss of $1.67 a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Blackstone, Coupang, Wells Fargo & Co
PAVmed Inc reports results for the quarter ended in December - Earnings Summary
PAVmed Inc expected to post a loss of $1.89 a share - Earnings Preview
PAVmed Inc expected to post a loss of $1.89 a share - Earnings Preview
Brief: PAVmed Issued Information Statement Relating To Distribution To Stockholders Of About 3.3 Mln Shares Of Lucid Diagnostics
Brief: PAVmed Elected To Receive $4.7 Million Fees & Reimbursements From Lucid Diagnostics